Health Technology Assessment (HTA) Support

Why choose Mtech Access for your HTA submission?

In many key markets, gaining approval by national reimbursement, pricing, or HTA agencies is critical to the commercial success of a new product launch.

We offer a full HTA service delivered in house by our highly experienced team of Market Access Writers, Health Economists, Literature Review Analysts, Medical Statisticians, and Consultants. Our multidisciplinary team delivers quality, consistency, and efficiency for our clients. Our support extends to pharmaceuticals, medical technologies, and diagnostics.

We will become an extension of your team, supporting you in building a robust HTA evidence package and strategy that can withstand scrutiny from any HTA body, optimising the likelihood of successful reimbursement.

High HTA success rates driven by experience

170+ HTA submissions^†
60+ years’ experience between our HTA, Evidence, and Health Economics Directors
We have team members with previous roles in NICE EAGs and SMC who can provide unique insights
We have a specialty in oncology and rare disease submissions, with a 100% success rate with UK submissions^‡

† Sets include at least one NICE, SMC, or NCPE submission; submissions worked on by Mtech Access team members in current and previous roles.
‡ As of September 2024.

Navigating complex HTA challenges

This expertise enables us to navigate challenges to ensure that all projects run as smoothly as possible, including:

Complex treatment pathways
Use of RWE data and/or data from proxy diseases to inform evidence package generation, including ITCs and models
Single-arm trials and lack of comparative data
Immature datasets
Early HTA submissions due to accelerated regulatory timelines (e.g. Orbis Type A, ILAP)
Tight HTA timelines, producing deliverables in a timely manner for submission

“

“It’s been a pleasure working with the Mtech Access dream team! Great outcomes achieved in our SMC appraisals and in a speedy fashion too! This is a massive achievement and almost unexpected, as less than 20% of Detailed Advice Documents (DADs) are positive, especially considering the complexity of this appraisal.”

HTA ManagerTop 20 Pharma

“

“[Mtech Access were] fantastic to work with [and] went over and above the standards expected”

Head of Market Access who commissioned a suite of UK HTA submissions

“

"Without Mtech Access we may have missed several deadlines, as we had multiple HTA submissions to coordinate and faced added disruption to timelines and processes due to the pandemic. The situation was challenging, and I don’t think we could have got through the process without the quality of the work, the complete understanding of the process, and fantastic project management delivered by Mtech Access.”
Head of Market Access, UK & Ireland Pharma Company

“

"The HTA strategy and gap analysis from Mtech Access was highly satisfying and exceeded all expectations. We were impressed by how comprehensive the research was, and how dedicated the team were. The project management and communication from the team was perfect. 10/10.”
Senior Market Access and Public Affairs Manager Top 20 Pharma Company

“

"The health economic modelling for our HTA submission was difficult and complex, but the Mtech Access Health Economist came up with lots of ideas, working with our team to overcome these challenges; it was just like having another colleague around the table."
Head of Market Access, UK & IrelandPharma Company

“

"The medical writing skill at Mtech Access was second to none. The writers were good at asking for direction when needed, which avoided rewrites and meant that the team got it spot on the first time around."
Head of Market Access, UK & IrelandPharma Company

“

“It was great to get insights on the HTA landscape. The desk research done by Mtech Access was really detailed and identified a lot of gaps, whilst the experts that Mtech Access interviewed added a lot of value. The insights we gained have helped support our engagement with NICE and other stakeholders.”
Health Economics ManagerTop 20 Pharma Company

“

“The HTA landscape review and strategy recommendations report has been a very useful resource as we develop our market access strategies across Europe, giving us insights on how to manage our product in different countries. We were very well supported by the Mtech Access team and the final presentation was done really well.”
Payer Engagement LeadTop 20 Pharma company

To discuss your HTA support needs with our experts, get in touch using the form below.

Health Technology Assessment (HTA) Support

Discover how we can help you overcome one of the most significant hurdles in market access… the HTA submission.

Health Technology Assessment (HTA) flyer - download now

DOWNLOAD BROCHURE

One of the first challenges faced by those new to HTA can be understanding the array of acronyms used by assessors and experts. We have compiled this list of commonly used acronyms and organisations to help you navigate the world of HTA.

View our HTA Definitions Guide

HTA submissions and reimbursement dossiers for key markets

We can support with reimbursement preparations and dossiers for key markets, including:

NICE STA, MTEP, and DAP

SMC, full, abbreviated, and ultra-orphan

AWMSG

NCPE, rapid review and full submissions

EU JCA

AMCP submissions and PIE decks

CADTH/CDA-AMC

PBAC

Our HTA services

We offer a full service, from strategy through to evidence generation, dossier writing, and post-submission support with full project management support for pharmaceutical products, medical devices (including digital health), and diagnostics. This can include:

Strategic and technical evidence review

Assessment of strengths/weaknesses of the supporting evidence package, building a mitigation strategy and new evidence generation plan
Multifaceted strategic and technical review of economic models to assess their suitability for the market(s) of interest
Critical appraisal of systematic reviews (and associated information retrieval methodology) and/or ITCs
EAG-style review of evidence packages/submission documents

Robust HTA strategy development

Deep dive into previous HTA submissions in the disease area (or an analogue disease) to identify key learnings
Assessment of the current treatment pathway and mapping of key relevant comparators
Strategic advice across the whole HTA process
Strategy workshops with optional expert consulting panel attendance

Applications for Scientific Advice

NICE/CADTH (now CDA-AMC) briefing book development

Expert (payers, clinicians, health economists) elicitation

HTA advisory boards
Strategy huddles and focus/steering groups
Structured expert elicitation, e.g. SHELF method, IDEA protocol, NGT, Delphi method
1:1 telephone interviews

Pre-submission support

For example, scoping and decision problem stages for NICE, ultra-orphan form for SMC

HTA-standard evidence package generation

HTA-ready (cost-effectiveness, cost-minimisation, cost-benefit, and budget impact) economic modelling
Targeted and systematic literature reviews
Feasibility assessment for evidence synthesis and ITC

HTA submission development

Full high-quality HTA submission pack, in line with the latest HTA agency guidelines

Applications for early access pathways

Application for an Innovation Passport through ILAP
PIM form for EAMS designation

Post-submission support

Complete post-submission support, including strategic advice, written responses, and economic and statistical analyses
Publications support, including abstracts, posters, and oral presentations